TCM
ENTA icon

Teza Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Teza Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,074
Closed -$313K – 244
2019
Q4 		$313K Buy
+5,074
New +$315K 0.09% 414
2018
Q3 		– Sell
-2,855
Closed -$331K – 425
2018
Q2 		$331K Buy
+2,855
New +$285K 0.05% 413

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Teza Capital Management's ENTA Position: Q1 2020 in Review

Teza Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 5,074 shares — an estimated $313K sold.

Teza Capital Management first reported a position in ENTA in Q2 2018 and held it in 2 quarters. The position peaked at $331K in Q2 2018. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

  • Teza Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Teza Capital Management sold 5,074 Enanta Pharmaceuticals shares in Q1 2020, an estimated $313K.
  • Teza Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Teza Capital Management's Enanta Pharmaceuticals position peaked at $331K in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Teza Capital Management's 13F filing for Q1 2020, filed 11 May 2020.